Malaysia’s Hovid Berhad and Singapore’s National Neuroscience Institute Signed MOU On Tocotrienol Parkinson’s Disease Research

Dear readers,

It is our pleasure to share with you that Hovid Berhad (one of Malaysia’s largest pharmaceutical companies) and the National Neuroscience Institute (NNI) of Singapore have signed a Memorandum of Understanding (MoU) to conduct research to study the neuroprotective effects of palm tocotrienol complex (EVNol SupraBio™) in Parkinson Disease.

Recent favorable research results of palm tocotrienol complex (EVNol SupraBio™) on neuroprotection especially in the areas of stroke and dementia have fueled this research collaboration between Hovid and NNI – to investigate the potential benefits of tocotrienols in Parkinson’s Diesease.

The Director of Research at NNI, Professor Tan Eng King has this to say –

“As Singapore’s national specialty centre for the management and treatment of neurological disease, we are keen to partner with Hovid Berhad to investigate the potential of palm tocotrienol as a preventative therapy for these diseases that affect a growing number of patients.”

The MoU and research collaboration were orginally reported in Issue 6 of Neuslink magazine (Jul – Dec 2015) – published by NNI, Singapore.

Click image below to load the PDF Palm Tocotrienols for Parkinson’s Disease.


Disclaimer : The statements in the above article have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure or prevent any disease.